Papillary thyroid cancer (PTC) is a common endocrine malignancy that frequently harbors
the oncogenic T1799A BRAF mutation. As a novel prognostic molecular marker, this …

Purpose For the past 65 years, patient age at diagnosis has been widely used as a major
mortality risk factor in the risk stratification of papillary thyroid cancer (PTC), but whether this …

Background: The clinical significance of papillary thyroid microcarcinoma (PTMC) tumors≤
1 cm is widely debated. The objective of this study was to compare conventional papillary …

Context: Radioiodine ablation is commonly used to treat thyroid cancer, but a major
challenge is often the loss of radioiodine avidity of the cancer caused by aberrant silencing …

A BRAF somatic mutation at residue 600 of the BRAF protein (BRAFV600E) is highly
prevalent in papillary thyroid carcinomas (PTC). This mutation occurs in approximately …

Background Adjuvant treatment with radioactive iodine (RAI) is often considered in the
treatment of well-differentiated thyroid carcinoma (WDTC). We explored the recollections of …

Background Intense disease surveillance and frequent lymph node metastases (LNMs) in
papillary thyroid cancer (PTC) have resulted in increased locoregional recurrences. We …

Radioiodine scintigraphy and therapy has played a major role in the treatment and follow-up
of thyroid cancer patients for decades. Single-photon emission computed …

Objective Thyroid cancer (TC) is the most common malignant endocrine-related cancer with
an increasing trend worldwide. Therefore, it's in urgent need to find new markers for …

Objective To evaluate a second‐generation assay for basal serum calcitonin (CT)
measurements compared with the pentagastrin‐stimulation test for the diagnosis of inherited …